| Abstract | Rituximab is a monoclonal antibody that targets the uniquely expressed B-cell CD20 receptor. Although recently approved for treatment of follicular lymphomas, the intracellular events that occur when rituximab binds to CD20 are largely unknown. Quantitative proteomic analysis of B-cell lymphoma-derived cells exposed to rituximab was performed. Differentially expressed proteins belonged to functional groups involved in migration, adhesion, calcium-induced signaling, ubiquitination, and components of the phosphoinositol and NF-kappaB pathways. Our studies reveal the proteomic consequences of rituximab treatment and provide novel insights into the mechanism of action of the drug in susceptible B-cell lymphoproliferative disorders. |
| Authors | Kathryn L Everton, David R Abbott, David K Crockett, Kojo S J Elenitoba-Johnson, Megan S Lim
(Affiliation: Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA.)
|
| Journal | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
(J Chromatogr B Analyt Technol Biomed Life Sci)
Vol. 877
Issue 13
Pg. 1335-43
(May 1 2009)
ISSN: 1873-376X [Electronic] Netherlands |
| PMID | 19010092
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Antibodies, Monoclonal
- Antineoplastic Agents
- Neoplasm Proteins
- rituximab
- Caspase 3
|
| Topics |
- Amino Acid Sequence
- Antibodies, Monoclonal
(pharmacology)
- Antineoplastic Agents
(pharmacology)
- Blotting, Western
- Caspase 3
(biosynthesis, metabolism)
- Chromatography, Liquid
- Databases, Protein
- Enzyme Induction
- Flow Cytometry
- Humans
- Lymphoma, Follicular
(metabolism, pathology)
- Molecular Sequence Data
- Neoplasm Proteins
(metabolism)
- Proteomics
- Tandem Mass Spectrometry
- Tumor Cells, Cultured
|
